Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
82VS
Boston, Massachusetts, United States82vs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
82VS serves as a biotech venture studio that leverages Alloy Therapeutics’ biologics and platform technologies to rapidly form asset-centric drug discovery companies, mostly in preclinical or early-stage development, with portfolio companies pursuing innovative programs in oncology, genetic diseases, autoimmune diseases, and related areas. Two companies, Broadwing Bio and Aakha Biologics, are noted as attracting significant investor interest for later-stage advancements
- Therapeutic areas
- ImmunologyOphthalmologyEndocrinologyNeurologyOncology
- Modalities
- AntibodyBispecific monoclonal antibodyTCR-mimic antibodyGenetic medicine
- Industry
- Investors
02
Partnerships
Alloy Therapeutics
Beyond the preview
Go deeper on 82VS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 82VS.